第一医药(600833) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥542,480,778.50, representing a year-on-year increase of 14.04%[3] - The total profit for the quarter was ¥52,374,952.68, a significant increase of 124.02% compared to the same period last year[3] - Net profit attributable to shareholders was ¥39,245,693.69, up 123.80% year-on-year[3] - The basic earnings per share for the quarter was ¥0.1759, reflecting a 123.79% increase compared to the previous year[3] - The net profit attributable to shareholders for the year-to-date was ¥53,269,885.92, down 63.84% compared to the previous year[3] - The net profit for the first three quarters of 2025 is CNY 54,020,386.58, a decrease from CNY 147,358,092.70 in the same period of 2024, representing a decline of approximately 63.4%[18] - Operating profit for the first three quarters of 2025 is CNY 63,455,424.94, down from CNY 153,647,524.75 in 2024, indicating a decrease of about 58.7%[18] - The total comprehensive income for the first three quarters of 2025 is CNY 74,974,927.96, down from CNY 146,660,041.96 in 2024, a decrease of approximately 48.9%[18] - Basic and diluted earnings per share for the first three quarters of 2025 are both CNY 0.2388, down from CNY 0.6604 in 2024, representing a decline of about 63.8%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,030,693,993.01, an increase of 2.56% from the end of the previous year[4] - Total assets as of September 30, 2025, amounted to CNY 2,030,693,993.01, up from CNY 1,980,057,333.84 at the end of 2024, an increase of 2.5%[14] - Total liabilities increased slightly to CNY 860,399,830.63 from CNY 835,659,103.08, reflecting a growth of 2.9%[13] - Shareholders' equity rose to CNY 1,170,294,162.38, compared to CNY 1,144,398,230.76 in 2024, an increase of 2.3%[14] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥24,541,621.52[3] - Cash flow from operating activities for the first three quarters of 2025 is CNY 24,541,621.52, compared to a negative cash flow of CNY 51,595,472.56 in the same period of 2024, showing a significant improvement[20] - The cash flow from investing activities for the first three quarters of 2025 is CNY 6,852,987.70, compared to CNY 4,793,074.33 in 2024, reflecting an increase of approximately 43.0%[21] - The total cash outflow from financing activities for the first three quarters of 2025 is CNY 190,377,229.39, compared to CNY 218,473,721.73 in 2024, indicating a decrease of approximately 12.9%[21] - The cash and cash equivalents at the end of the period for 2025 is CNY 368,615,925.25, up from CNY 277,907,854.36 in 2024, indicating a growth of about 32.6%[21] Operational Metrics - Total operating revenue for the first three quarters of 2025 reached CNY 1,539,077,117.96, an increase of 12.4% compared to CNY 1,368,880,300.43 in the same period of 2024[17] - Total operating costs for the first three quarters of 2025 were CNY 1,536,044,900.73, up from CNY 1,367,296,395.88 in 2024, reflecting a growth of 12.4%[17] - Operating profit margin improved, with operating costs as a percentage of revenue decreasing from 100.1% in 2024 to 99.9% in 2025[17] - The company reported a net profit for the first three quarters of 2025, with a profit margin improvement due to cost management strategies implemented during the period[17] Inventory and Receivables - Inventory increased significantly to CNY 406,629,703.58, compared to CNY 336,323,956.50 in 2024, marking a rise of 20.9%[12] - Accounts receivable decreased to CNY 172,162,204.84 from CNY 189,373,266.78, a reduction of 9.4%[11] Other Information - The company received compensation for property expropriation, which significantly impacted the profit figures for the quarter[5] - The weighted average return on equity decreased by 9.25 percentage points to 4.64% year-to-date[3] - The company reported non-recurring gains and losses totaling ¥38,619,257.70 for the quarter[6] - The company has not executed any mergers or acquisitions during the reporting period[22]